2020 has tabled many unforeseen challenges as well as opportunities to the Life Science division, most notably of course, with the world population relying on services and solutions provided mostly by biotech and pharmaceutics enterprises. Nonetheless, along with the necessity of being skilled and prepared for facing new versions of the COVID 19, a demand for safer drugs, more liability, and greater value from the life science industry is heightening.
- Published on
